CytRx Corporation  

(Public, NASDAQ:CYTR)   Watch this stock  
Find more results for CYTR
+0.007 (1.27%)
Dec 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.51 - 0.53
52 week 0.41 - 3.66
Open 0.52
Vol / Avg. 968,423.00/1.33M
Mkt cap 52.02M
P/E     -
Div/yield     -
EPS -0.93
Shares 96.94M
Beta 1.39
Inst. own 30%
Mar 9, 2017
Q4 2016 CytRx Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 29, 2016
CytRx Corp Conference Call to Discuss Results of Phase 3 Trial of Aldoxorubicin - Webcast
Nov 9, 2016
Q3 2016 CytRx Corp Earnings Release
Sep 12, 2016
CytRx Corp at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -58587.19%
Operating margin - -63278.13%
EBITD margin - -62960.48%
Return on average assets -78.61% -76.73%
Return on average equity -208.01% -104.63%
Employees 31 -
CDP Score - -


11726 San Vicente Blvd Ste 650
LOS ANGELES, CA 90049-5079
United States - Map
+1-310-8265648 (Phone)
+1-310-8266139 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Officers and directors

John Y Caloz Chief Financial Officer
Age: 63
Bio & Compensation  - Reuters
Daniel J Levitt M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Douglas Scott Wieland Ph.D. Senior Vice President - Drug Development
Age: 56
Bio & Compensation  - Reuters
David J. Haen Vice President - Business Development
Age: 37
Bio & Compensation  - Reuters
Olivia C. Ware Chief Commercial Officer
Bio & Compensation  - Reuters
Steven A. Kriegsman Chairman of the Board, President, Chief Executive Officer
Age: 73
Bio & Compensation  - Reuters
Joseph Rubinfeld Ph.D. Lead Independent Director
Age: 83
Bio & Compensation  - Reuters
Earl W. Brien M.D. Director
Age: 56
Bio & Compensation  - Reuters
Anita J. Chawla Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Louis J. Ignarro Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters